# Cardioacc

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardioacc

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Total disclosed funding: $14M
- Latest round: Series A (Oct 27, 2025)
- Investors on record: 4

## About

Established in 2021 and based in Shenzhen, China, Shenzhen Xinhuan Technology Co., Ltd., trading under the name Cardioacc, is a medical device company focusing on the development of interventional imaging products. The company has more than twenty core invention patents. The core team is mainly from Imperial College, Johns Hopkins University, and the Chinese Academy of Sciences. In December 2025, Cardioacc raised a venture funding from new investor Huaxin Capital.

The company mainly develops cardiovascular interventional imaging and treatment technology and has initially completed the construction of ICE catheters, electromagnetic positioning, imaging algorithms, and other technologies. It is dedicated to developing 2D and 4D intra-cardiac ultrasound and has launched a 4D ICE system, which integrates multiple ultrasound imaging technologies such as soft beam synthesis and arbitrary waveform emission. And the registration clinical trial of the 7.5F 2D intracardiac ultrasound imaging system (ICE) was started.

The company generates revenue through the sale of medical imaging devices and related accessories to hospitals and healthcare institutions.

## Funding rounds

- Series A, Oct 27, 2025, $14M — YuanBio Venture, Tongfang Investment, Meizhong Capital Investment Management, Zhuhai Beiqinghe Investment Fund Management Co., Ltd.
- Angel, Sep 26, 2022 — YuanBio Venture

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel, Series A
- Tongfang Investment — Series A
- Meizhong Capital Investment Management (https://capitalatlas.ai/funds/meizhong-capital-investment-management) — Series A
- Zhuhai Beiqinghe Investment Fund Management Co., Ltd. — Series A